JY
PHAS

Jeff Yass’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Jeff Yass’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-273,100
Closed -$443K – 14436
2021
Q4 		$713K Buy
273,100
+92,741
+51% +$280K ﹤0.01% 8208
2021
Q3 		$561K Buy
180,359
+123,075
+215% +$411K ﹤0.01% 9080
2021
Q2 		$213K Buy
57,284
+499
+0.9% +$1.66K ﹤0.01% 11475
2021
Q1 		$196K Buy
56,785
+28,496
+101% +$116K ﹤0.01% 11441
2020
Q4 		$95K Sell
28,289
-1,364
-5% -$4.88K ﹤0.01% 10517
2020
Q3 		$104K Buy
29,653
+18,424
+164% +$74.2K ﹤0.01% 9898
2020
Q2 		$52K Buy
+11,229
New +$49.7K ﹤0.01% 9740
2019
Q2 		– Sell
-42,845
Closed -$407K – 11055
2019
Q1 		$407K Buy
+42,845
New +$170K ﹤0.01% 6668

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Jeff Yass's PHAS Position: Q1 2022 in Review

Jeff Yass sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2022, closing a stake of 273,100 shares — an estimated $443K sold.

Jeff Yass first reported a position in PHAS in Q1 2019 and held it in 8 quarters. The position peaked at $713K in Q4 2021. 56 funds tracked by Wall St. Rank hold PHAS as of Q1 2022.

  • Jeff Yass reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Jeff Yass sold 273,100 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $443K.
  • Jeff Yass first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
  • Jeff Yass's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $713K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Susquehanna International Group's 13F filing for Q1 2022, filed 16 May 2022.